Related references
Note: Only part of the references are listed.Combination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model
Ananth K. Vellimana et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2011)
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
David A. Reardon et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Bevacizumab for the Treatment of Recurrent Glioblastoma
Marc C. Chamberlain
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
IMPROVED INTRATUMORAL OXYGENATION THROUGH VASCULAR NORMALIZATION INCREASES GLIOMA SENSITIVITY TO IONIZING RADIATION
Mackenzie C. McGee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation
Joost J. C. Verhoeff et al.
CANCER LETTERS (2009)
Glioblastoma multiforme: a review of where we have been and where we are going
Cory Adamson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
SAFETY AND EFFICACY OF BEVACIZUMAB WITH HYPOFRACTIONATED STEREOTACTIC IRRADIATION FOR RECURRENT MALIGNANT GLIOMAS
Philip H. Gutin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme
Matthew J. McGirt et al.
JOURNAL OF NEUROSURGERY (2009)
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gary L. Gallia et al.
MOLECULAR CANCER THERAPEUTICS (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model
Sarah Brem et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Hypoxic radiosensitization: Adored and ignored
Jens Overgaard
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Current status of angiogenesis inhibitors combined with radiation therapy
Carsten Nieder et al.
CANCER TREATMENT REVIEWS (2006)
Local delivery of antineoplastic agents by controlled-release polymers for the treatment of malignant brain tumours
SM Raza et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Targeted therapy for brain tumours
MS Lesniak et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma
JL Frazier et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Share Paper
